Koers MabVax Therapeutics Holdings, Inc.
Aandelen
MBVXQ
US55414P7024
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- USD | -.--% | +10,05% | +182,21% |
Omzet 2016 | 148K 137K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,38 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,78 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,64 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 437K | Nettoschuld 2017 | 2,48 mln. 2,3 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+182,21% | 213K | |
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |